Expert perspectives on the design and communication of endpoints in Alzheimer’s disease clinical trials

by Clinical Neuropsychologist Online | Friday, October 30, 2026 | Dementia

Abstract Disease-targeted therapies (DTTs) for Alzheimer’s disease (AD) represent a major advance, yet challenges remain on how best to interpret and communicate their benefits. As clinical development increasingly targets the earliest stages of AD (before...

Retinal microvasculature alterations are associated with mild behavioral impairment in Southeast Asian dementia‐free older adults

by Clinical Neuropsychologist Online | Friday, October 30, 2026 | Dementia

Abstract BACKGROUND Mild behavioral impairment (MBI) is an important neurobehavioral marker of dementia. This study examined associations between retinal vascular measures, MBI, and its potential neurobiological correlates. METHODS Dementia-free older adults from a...

Deep learning‐based prediction of regional brain Tau PET burden from MRI

by Clinical Neuropsychologist Online | Friday, October 30, 2026 | Dementia

Abstract INTRODUCTION Regional tau is strongly associated with Alzheimer’s disease (AD) symptoms, but tau positron emission tomography (PET) is not routinely available, limiting early risk stratification. METHODS We trained a deep learning model to predict...

Exploring Quality of Life Through Residents’ Voice in Nursing Homes: A Qualitative Study of a Montessori-Based Person-Centered Model of Care

by Clinical Neuropsychologist Online | Friday, October 30, 2026 | Dementia

Dementia, Ahead of Print. Person-centered care (PCC) is the gold standard for improving the quality of life (QoL) of people living with dementia. The Montessori method represents a practical model for implementing PCC in Nursing Homes (NHs). To date, no study has...

APOE ε4 gene dose drives a canonical and predictable topography of amyloid deposition

by Clinical Neuropsychologist Online | Friday, October 30, 2026 | Dementia

Abstract INTRODUCTION Apolipoprotein E ε4 (APOE ε4) carriership is associated with higher amyloid burden in Alzheimer’s disease (AD), but whether it constrains the spatial predictability of amyloid deposition at the individual level remains unknown. METHODS We...

ARRDC4 drives Tau pathology via USP14‐mediated deubiquitination and acts as a novel therapeutic target in Alzheimer’s disease

by Clinical Neuropsychologist Online | Friday, October 30, 2026 | Dementia

Abstract INTRODUCTION Hyperphosphorylated Tau accumulation drives neurodegeneration in Alzheimer’s disease (AD), but mechanisms linking impaired Tau ubiquitination to disease progression remain incompletely defined. METHODS We integrated Drosophila RNAi...